Delcath Systems, Inc. (NASDAQ:DCTH) Receives $23.17 Average PT from Brokerages

Shares of Delcath Systems, Inc. (NASDAQ:DCTH) have received a consensus rating of “Moderate Buy” from the seven analysts that are covering the firm, Marketbeat.com reports. One investment analyst has rated the stock with a sell recommendation, five have issued a buy recommendation and one has given a strong buy recommendation to the company. The average 12 month price objective among brokerages that have issued ratings on the stock in the last year is $23.1667.

A number of equities research analysts have weighed in on the stock. Zacks Research upgraded shares of Delcath Systems from a “hold” rating to a “strong-buy” rating in a report on Monday, August 10th. BTIG Research lifted their target price on shares of Delcath Systems from $17.00 to $21.00 and gave the company a “buy” rating in a report on Thursday, August 6th. HC Wainwright reissued a “buy” rating and issued a $32.00 price target (up from $30.00) on shares of Delcath Systems in a research report on Friday, August 7th. Weiss Ratings downgraded Delcath Systems from a “sell (d+)” rating to a “sell (d)” rating in a research note on Friday, August 21st. Finally, Wall Street Zen upgraded Delcath Systems from a “hold” rating to a “buy” rating in a research note on Saturday, August 8th.

Institutional Investors Weigh In On Delcath Systems

Hedge funds have recently added to or reduced their stakes in the stock. Deutsche Bank AG raised its holdings in Delcath Systems by 5.4% in the 4th quarter. Deutsche Bank AG now owns 24,162 shares of the company’s stock worth $244,000 after acquiring an additional 1,248 shares during the last quarter. California State Teachers Retirement System bought a new position in Delcath Systems in the 2nd quarter valued at approximately $26,000. Intech Investment Management LLC boosted its stake in Delcath Systems by 13.1% during the 4th quarter. Intech Investment Management LLC now owns 17,595 shares of the company’s stock valued at $178,000 after purchasing an additional 2,035 shares during the last quarter. AWM Investment Company Inc. boosted its stake in Delcath Systems by 3.9% during the 4th quarter. AWM Investment Company Inc. now owns 60,000 shares of the company’s stock valued at $606,000 after purchasing an additional 2,279 shares during the last quarter. Finally, Royal Bank of Canada increased its holdings in shares of Delcath Systems by 14.8% in the 1st quarter. Royal Bank of Canada now owns 18,383 shares of the company’s stock worth $170,000 after purchasing an additional 2,364 shares in the last quarter. 61.12% of the stock is owned by institutional investors.

Delcath Systems Stock Performance

Shares of DCTH stock opened at $16.34 on Monday. The company’s fifty day moving average price is $14.03 and its 200-day moving average price is $11.60. The stock has a market cap of $567.00 million, a PE ratio of 1,635.64 and a beta of 0.52. Delcath Systems has a 12 month low of $8.12 and a 12 month high of $17.42.

Delcath Systems (NASDAQ:DCTH) last issued its quarterly earnings results on Thursday, August 6th. The company reported $0.07 earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.09) by $0.16. Delcath Systems had a net margin of 0.56% and a return on equity of 0.46%. The company had revenue of $29.13 million during the quarter, compared to analyst estimates of $26.25 million. On average, sell-side analysts forecast that Delcath Systems will post -0.17 earnings per share for the current fiscal year.

Delcath Systems Company Profile

Delcath Systems, Inc is a specialty pharmaceutical and medical technology company focused on the development and commercialization of its proprietary Hepatic CHEMOSAT® Delivery System, designed to deliver high-dose chemotherapeutic agents directly to the liver while minimizing systemic exposure. The company’s core technology performs isolated hepatic perfusion, enabling oncologists to administer concentrated melphalan to patients with primary and metastatic liver tumors, including those arising from ocular melanoma.